Dual Specificity Mitogen Activated Protein Kinase Kinase 1 (ERK Activator Kinase 1 or MAPK/ERK Kinase 1 or MAP2K1 or EC 2.7.12.2) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Dual Specificity Mitogen Activated Protein Kinase Kinase 1 (ERK Activator Kinase 1 or MAPK/ERK Kinase 1 or MAP2K1 or EC 2.7.12.2) - Pipeline Review, H2 2016

Dual Specificity Mitogen Activated Protein Kinase Kinase 1 (ERK Activator Kinase 1 or MAPK/ERK Kinase 1 or MAP2K1 or EC 2.7.12.2) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Dual Specificity Mitogen Activated Protein Kinase Kinase 1 (ERK Activator Kinase 1 or MAPK/ERK Kinase 1 or MAP2K1 or EC 2.7.12.2) - Pipeline Review, H2 2016
Published Jul 20, 2016
110 pages — Published Jul 20, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Dual Specificity Mitogen Activated Protein Kinase Kinase 1 (ERK Activator Kinase 1 or MAPK/ERK Kinase 1 or MAP2K1 or EC 2.7.12.2) - Pipeline Review, H2 2016, provides in depth analysis on Dual Specificity Mitogen Activated Protein Kinase Kinase 1 (ERK Activator Kinase 1 or MAPK/ERK Kinase 1 or MAP2K1 or EC 2.7.12.2) targeted pipeline therapeutics.

The report provides comprehensive information on the Dual Specificity Mitogen Activated Protein Kinase Kinase 1 (ERK Activator Kinase 1 or MAPK/ERK Kinase 1 or MAP2K1 or EC 2.7.12.2) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Dual Specificity Mitogen Activated Protein Kinase Kinase 1 (ERK Activator Kinase 1 or MAPK/ERK Kinase 1 or MAP2K1 or EC 2.7.12.2) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Dual Specificity Mitogen Activated Protein Kinase Kinase 1 (ERK Activator Kinase 1 or MAPK/ERK Kinase 1 or MAP2K1 or EC 2.7.12.2)
- The report reviews Dual Specificity Mitogen Activated Protein Kinase Kinase 1 (ERK Activator Kinase 1 or MAPK/ERK Kinase 1 or MAP2K1 or EC 2.7.12.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Dual Specificity Mitogen Activated Protein Kinase Kinase 1 (ERK Activator Kinase 1 or MAPK/ERK Kinase 1 or MAP2K1 or EC 2.7.12.2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Dual Specificity Mitogen Activated Protein Kinase Kinase 1 (ERK Activator Kinase 1 or MAPK/ERK Kinase 1 or MAP2K1 or EC 2.7.12.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related

  
Source:
Document ID
GMDHC0405TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents25
  List of Tables51
  List of Figures61
Introduction71
  Global Markets Direct Report Coverage71
Dual Specificity Mitogen Activated Protein Kinase Kinase 1 (ERK Activator Kinase 1 or MAPK/ERK Kinase 1 or MAP2K1 or EC 2.7.12.2) Overview81
Therapeutics Development94
  Dual Specificity Mitogen Activated Protein Kinase Kinase 1 (ERK Activator Kinase 1 or MAPK/ERK Kinase 1 or MAP2K1 or EC 2.7.12.2) Products under Development by Stage of Development91
  Dual Specificity Mitogen Activated Protein Kinase Kinase 1 (ERK Activator Kinase 1 or MAPK/ERK Kinase 1 or MAP2K1 or EC 2.7.12.2) Products under Development by Therapy Area101
  Dual Specificity Mitogen Activated Protein Kinase Kinase 1 (ERK Activator Kinase 1 or MAPK/ERK Kinase 1 or MAP2K1 or EC 2.7.12.2) Products under Development by Indication112
Dual Specificity Mitogen Activated Protein Kinase Kinase 1 (ERK Activator Kinase 1 or MAPK/ERK Kinase 1 or MAP2K1 or EC 2.7.12.2) Pipeline Products Glance132
  Late Stage Products131
  Early Stage Products141
Dual Specificity Mitogen Activated Protein Kinase Kinase 1 (ERK Activator Kinase 1 or MAPK/ERK Kinase 1 or MAP2K1 or EC 2.7.12.2) Products under Development by Companies156
Dual Specificity Mitogen Activated Protein Kinase Kinase 1 (ERK Activator Kinase 1 or MAPK/ERK Kinase 1 or MAP2K1 or EC 2.7.12.2) Therapeutics Assessment216
  Assessment by Monotherapy/Combination Products211
  Assessment by Mechanism of Action221
  Assessment by Route of Administration232
  Assessment by Molecule Type252
Dual Specificity Mitogen Activated Protein Kinase Kinase 1 (ERK Activator Kinase 1 or MAPK/ERK Kinase 1 or MAP2K1 or EC 2.7.12.2) Companies Involved in Therapeutics Development279
  Array BioPharma Inc.271
  AstraZeneca Plc281
  Eisai Co., Ltd.291
  F. Hoffmann-La Roche Ltd.301
  GlaxoSmithKline Plc311
  Merck &Co., Inc.321
  Merck KGaA331
  Novartis AG342
Dual Specificity Mitogen Activated Protein Kinase Kinase 1 (ERK Activator Kinase 1 or MAPK/ERK Kinase 1 or MAP2K1 or EC 2.7.12.2) Drug Profiles3647
  binimetinib Drug Profile367
  binimetinib + encorafenib Drug Profile432
  CIP-137401 Drug Profile451
  cobimetinib fumarate Drug Profile466
  dabrafenib mesylate + durvalumab + trametinib dimethyl sulfoxide Drug Profile521
  dabrafenib mesylate + panitumumab + trametinib dimethyl sulfoxide Drug Profile531
  dabrafenib mesylate + trametinib dimethyl sulfoxide Drug Profile547
  E-6201 Drug Profile612
  EBI-1051 Drug Profile631
  MK-2206 + selumetinib sulfate Drug Profile641
  pimasertib hydrochloride Drug Profile653
  pimasertib hydrochloride + voxtalisib Drug Profile682
  RG-7304 Drug Profile701
  selumetinib sulfate Drug Profile715
  trametinib dimethyl sulfoxide Drug Profile765
  trametinib dimethyl sulfoxide + uprosertib Drug Profile812
Dual Specificity Mitogen Activated Protein Kinase Kinase 1 (ERK Activator Kinase 1 or MAPK/ERK Kinase 1 or MAP2K1 or EC 2.7.12.2) Dormant Projects838
Dual Specificity Mitogen Activated Protein Kinase Kinase 1 (ERK Activator Kinase 1 or MAPK/ERK Kinase 1 or MAP2K1 or EC 2.7.12.2) Discontinued Products912
Dual Specificity Mitogen Activated Protein Kinase Kinase 1 (ERK Activator Kinase 1 or MAPK/ERK Kinase 1 or MAP2K1 or EC 2.7.12.2) Featured News &Press Releases9316
  Jun 30, 2016: Array BioPharma Submits Binimetinib New Drug Application to U.S. FDA931
  Jun 06, 2016: Array Presents Full Results from Phase 3 NEMO Study941
  Jun 06, 2016: Novartis combination therapy Tafinlar + Mekinist demonstrates overall survival benefit at three-year follow-up in patients with advanced melanoma951
  Jun 06, 2016: Novartis pivotal data for Tafinlar + Mekinist demonstrated a 63 percent overall response rate in treating rare form of lung cancer961
  Jun 05, 2016: Exelixis Announces Genentech Presentation of Preliminary Phase 1B Trial Results for the Combination of Cobimetinib and Atezolizumab at ASCO 2016 Annual Meeting971
  Jun 03, 2016: Cobimetinib in advanced melanoma with BRAF V600 mutation: Added benefit now considerable981
  May 18, 2016: Array BioPharma Announces Key Data from NRAS-mutant Melanoma at ASCO 2016991
  May 12, 2016: Selumetinib granted Orphan Drug Designation in the US for adjuvant treatment of differentiated thyroid cancer1001
  Apr 29, 2016: NICE recommends combined drug therapy proven to extend life for skin cancer1011
  Apr 20, 2016: Exelixis Announces Presentation On Cobimetinib At 2016 ASCO Annual Meeting1012
  Apr 01, 2016: Array BioPharma Announces Decision To Discontinue MILO Study In Ovarian Cancer1031
  Mar 22, 2016: Many Targeted Cancer Therapies Suppress T Cell Immune Responses1031
  Feb 25, 2016: New targeted therapy for treatment of serious form of skin cancer approved in Canada1042
  Jan 13, 2016: Dabrafenib/trametinib in advanced BRAF V600 mutated melanoma: Indication of added benefit1061
  Dec 16, 2015: Array BioPharma Announces Phase 3 Binimetinib Trial Meets Primary Endpoint For NRAS-Mutant Melanoma1072
Appendix1092
  Methodology1091
  Coverage1091
  Secondary Research1091
  Primary Research1091
  Expert Panel Validation1091
  Contact Us1091
  Disclaimer1101

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Dual Specificity Mitogen Activated Protein Kinase Kinase 1 (ERK Activator Kinase 1 or MAPK/ERK Kinase 1 or MAP2K1 or EC 2.7.12.2) - Pipeline Review, H2 2016" Jul 20, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Dual-Specificity-Mitogen-Activated-Protein-Kinase-Kinase-1-ERK-Activator-Kinase-1-or-MAPK-ERK-Kinase-1-or-MAP2K1-or-EC-2-7-12-2-Pipeline-Review-H2-2016-2088-16287>
  
APA:
Global Markets Direct - Market Research. (2016). Dual Specificity Mitogen Activated Protein Kinase Kinase 1 (ERK Activator Kinase 1 or MAPK/ERK Kinase 1 or MAP2K1 or EC 2.7.12.2) - Pipeline Review, H2 2016 Jul 20, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Dual-Specificity-Mitogen-Activated-Protein-Kinase-Kinase-1-ERK-Activator-Kinase-1-or-MAPK-ERK-Kinase-1-or-MAP2K1-or-EC-2-7-12-2-Pipeline-Review-H2-2016-2088-16287>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.